‘Love Hormone’ Treatment Makes Lions Friendlier, New Study

Lions are seen at the Artis Amsterdam Royal Zoo in Amsterdam, Netherlands in this handout photo released to media on January 28, 2021. Picture taken September 7, 2020. Artis Amsterdam Royal Zoo/Handout via REUTERS
Lions are seen at the Artis Amsterdam Royal Zoo in Amsterdam, Netherlands in this handout photo released to media on January 28, 2021. Picture taken September 7, 2020. Artis Amsterdam Royal Zoo/Handout via REUTERS
TT

‘Love Hormone’ Treatment Makes Lions Friendlier, New Study

Lions are seen at the Artis Amsterdam Royal Zoo in Amsterdam, Netherlands in this handout photo released to media on January 28, 2021. Picture taken September 7, 2020. Artis Amsterdam Royal Zoo/Handout via REUTERS
Lions are seen at the Artis Amsterdam Royal Zoo in Amsterdam, Netherlands in this handout photo released to media on January 28, 2021. Picture taken September 7, 2020. Artis Amsterdam Royal Zoo/Handout via REUTERS

Lions typically aren't keen on making new friends. The giant cats guard their territory fiercely and can mortally wound a foe with a single swipe. While aggression is an advantage for apex predators in the wild, it poses real challenges for lions on reserves or in captivity, a number that is growing due to habitat loss.

Researchers working on a wildlife reserve in Dinokeng, South Africa, found that an intranasal application of the "love hormone" oxytocin could make lion meet-cutes less life-threatening. Their work appeared March 30 in the journal iScience.

In the summers of 2018 and 2019, a team led by animal biologist Craig Packer and neuroscientist Sarah Heilbronner from the University of Minnesota spent their days using hunks of raw meat to lure lions up to a fence so they could spray oxytocin up their noses with a tool that looks like an antique perfume bottle.

By spraying the oxytocin directly up the nose, it can travel up the trigeminal nerve and the olfactory nerve straight up into the brain.

After these treatments, researchers observed that the 23 lions who were given oxytocin were more tolerant of other lions in their space and displayed less vigilance towards intruders.

"You can see their features soften immediately, they go from wrinkled and aggressive to this totally calm demeanor. They totally chill out. It's amazing," said Jessica Burkhart from the Department of Ecology, Evolution and Behavior at the University of Minnesota, in a report posted on the Cell Press network.

Researchers measure social tolerance by seeing how close a lion who has possession of a desired object, in this case a pumpkin toy, will let others approach it.

"After the lions were treated with oxytocin, and we gave them their favorite pumpkin toy to play with, we saw the average distance between them drop from about 7 meters with no treatment to about 3.5 meters after oxytocin was administered,” added Burkhart.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”